“
Metformin remains the drug of choice
for first-line therapy
”
1
…
“
should
be initiated concurrent with lifestyle
intervention at diagnosis
”
2
“
Consider extended-release tablets when
GI side effects prevent continuation of
metformin therapy
”
3
Society for Endocrinology,Metabolism
andDiabetes of SouthAfrica
Low incidence of GI side effects
4
Powerful glycaemic control
5
Significantly improved adherence
to treatment
6
No weight gain
7
For newly diagnosed Type 2 Diabetes patients
and those intolerant to immediate-release metformin
due to gastrointestinal side effects
NEW
CONSENSUS
References:1.
IDFClinicalGuidelinesTaskForce.GlobalGuidelinesforType2diabetes.Brussels:InternationalDiabetesFederation,2005.
2.
NathanDM,BuseJB,DavidsonMB,
etal.
ManagementofhyperglycaemiainType2diabetes:aconsensusalgorithmfortheinitiationandadjustmentoftherapy. AconsensusstatementfromtheAmericanDiabetesAssociationandtheEuropeanAssociationfortheStudyofDiabetes.
Diabetologica
2006;49(8):1711-1721.
3.
SEMDSAGuidelinesforDiagnosisand
ManagementofType2DiabetesMellitusforPrimaryHealthCare.
JEMDSA
2009;14(1):55-58.
4.
BlondeL,DaileyGE,JabbourSA,ReasnerCA,MillsDJ.GastrointestinaltolerabilityofGlucophage
®
XRextended-releasetabletscomparedtoimmediate-releaseGlucophage
®
tablets- resultsofaretrospectivecohortstudy.
CurrMedResOpin
2004
;
20
:
565-572.
5.
FujiokaK,
etal
.Efficacy,dose-responserelationshipandsafetyofonce-dailyextended-releasemetformin(Glucophage
®
XR)intype2diabetic
patientswithinadequateglycemiccontroldespitepriortreatmentwithdietandexercise:resultsfromtwodouble-blind,placebo-controlledstudies.
CurrentTherapeutics
Vol25,No2:2003
.
6.
DonnellyLA,MorrisAD,PearsonER.Adherenceinpatientstransferredfromimmediate-releasemetformintoasustainedreleaseformulation:apopulation-basedstudy.
Diabetes,ObesityandMetabolism
2009;11:338-342.
7.
FujiokaK,JoyalS,BruceS.Type2Diabetespatientsswitchedfromimmediate-release
metforminbidtoanextendedreleaseqdformulationinarandomized,controlledtrialmaintainedcomparableglycaemiccontrol.
ClinTher
2003;25:515-529.
S3
GLUCOPHAGE
®
XR500mgModifiedReleaseTablet.EachModifiedReleaseGLUCOPHAGE
®
XRtabletcontains500mgmetforminhydrochloride.Reg.No.A39/21.2/0027.
For full prescribing information, please refer to approved package insert
MERCK
(PTY) LTD,Reg.no.: 1970/004059/07. 1 FrieslandDrive, LongmeadowBusiness Estate South,Modderfontein 1645. Tel: 011 372 5000 Fax: 011 372 5252.
ZA.G/GXR/GV.10.07.03 131123
Start
Right…
MerckSerono
Merck Pharma Customer Call Centre 08611 MERCK or 08611 63725.
CardioMetabolic Care
